Phase II NASH clinical data show ASC40 significantly reduces liver fat content

In this randomized, placebo-controlled Phase II clinical study (FASCINATE-1), clinical researchers assessed the safety and efficacy of TVB-2640 in 99 U.SNASH patients, administered once a day for 12 weeksThe subject's baseline met liver fat content of more than or equal to 8% (as determined by MRI-PDFF), accompanied by liver fibrosis F1-F3The study showed a relative reduction in liver fat content by 28.2% in the 50 mg dose group, while liver fat content increased by 4.5% in the placebo groupAfter 12 weeks of administration, TVB-2640 also significantly reduced glutamate transaminase (ALT) by 20.4% and LDL-cholesterol by 7.6%The decrease in these indicators indicates an improvement in liver function and metabolic levelsTVB-2640 showed good tolerance, benign adverse events are mainly level 1 events, no serious adverse eventsthe screening of NASH patients in a 50 mg dose clinical trial in China has begun, with 25-30 people in the groupalso has two other in-house developments for NASH candidatesASC41 is a highly active, selective thyroid hormone beta receptor (THR-beta) agonisant whose clinical trial application has been approved by the State Drug Administration of ChinaThe study will be administered with oral tablets developed by Clarissian know-how and is expected to have top-line data (TOPline results) for phase I clinical studies of safety, pharmacokinetics and initial efficacy (LDL-C) by the end of 2020ASC42 is a NASH candidate drug in the pre-IND phase for another targetThe three candidate drugs laid out in the NASH field are in different stages of development and can be used individually or jointly, making Theme internationally competitive(The original text has a cut)